NAV
$41.01
AUM
$23.0M
Expense Ratio
-
Dividend Yield
0.00%
Beta
1.04
Currency
USD
| YTD | 1M | 3M | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| +12.71% | +17.59% | +23.01% | +47.99% | +11.03% | -4.54% |
| # | Symbol | Name | Weight |
|---|---|---|---|
| 1 | GH | Guardant Health Inc | 8.85% |
| 2 | NTRA | Natera Inc | 6.92% |
| 3 | KRYS | Krystal Biotech Inc | 5.93% |
| 4 | UTHR | United Therapeutics Corp | 4.06% |
| 5 | LGND | Ligand Pharmaceuticals Inc | 3.82% |
| 6 | BBIO | BridgeBio Pharma Inc | 3.51% |
| 7 | ADPT | Adaptive Biotechnologies Corp | 3.17% |
| 8 | LLY | Eli Lilly and Co | 3.07% |
| 9 | AZN.L | AstraZeneca PLC | 2.98% |
| 10 | VRTX | Vertex Pharmaceuticals Inc | 2.79% |
Under normal market conditions, the fund invests at least 80% of its net assets in equity securities of companies that are relevant to its investment theme of genomic advancements. The fund invests predominantly in common stock. Although it may invest across economic sectors, the fund concentrates its investments in health care related industries. It is non-diversified.
Inception Date: 2020-02-25